Compliance Rate

Compliance Rate 51.23%
Compliant submissions 187
Incompliant submissions 178
Total trials 365

My Organizations' Clinical Trials

Showing 150 of 2400 entries
View as:

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

Phase: N/A Priority: Normal
NCT ID: NCT00515827 Org: User:
Start: 11/30/07 End: 11/30/08 Due: 11/30/09

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

Phase: N/A Priority: Normal
NCT ID: NCT01230814 Org: User:
Start: 04/30/11 End: 08/31/13 Due: 08/31/14

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05184452 Org: User:
Start: 11/15/21 End: 07/19/23 Due: 07/19/24

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

Phase: N/A Priority: Normal
NCT ID: NCT02852005 Org: User:
Start: 01/31/17 End: 10/29/19 Due: 10/29/20

Social and Economic Outcomes of HIV/AIDS Care and Treatment in HIV Infected South African Adults

Phase: N/A Priority: Normal
NCT ID: NCT00270764 Org: User:
Start: 07/31/05 End: 09/30/13 Due: 09/30/14

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

Phase: N/A Priority: Normal
NCT ID: NCT02890381 Org: User:
Start: 10/05/16 End: 04/24/17 Due: 04/24/18

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00001090 Org: User:
Start: - End: 10/31/99 Due: 10/31/00

Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT03478891 Org: User:
Start: 05/16/18 End: 03/20/19 Due: 03/20/20

Influenza Vaccine in Pregnant Women

Phase: N/A Priority: Normal
NCT ID: NCT00905125 Org: User:
Start: 06/30/09 End: 03/31/10 Due: 03/31/11

Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02484417 Org: User:
Start: 07/21/15 End: 08/10/16 Due: 08/10/17

Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT02475655 Org: User:
Start: 05/16/16 End: 04/04/18 Due: 04/04/19

Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients

Phase: N/A Priority: Normal
NCT ID: NCT00290823 Org: User:
Start: 04/30/06 End: 03/31/11 Due: 03/31/12

Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00001651 Org: User:
Start: 02/25/98 End: 05/29/20 Due: 05/29/21

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

Phase: N/A Priority: Normal
NCT ID: NCT00486408 Org: User:
Start: 07/31/07 End: 11/30/12 Due: 11/30/13

Genetic Risk Factors for Severe Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00090740 Org: User:
Start: 09/30/04 End: 01/31/05 Due: 01/31/06

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

Phase: N/A Priority: Normal
NCT ID: NCT00027261 Org: User:
Start: - End: 12/31/05 Due: 12/31/06

Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)

Phase: N/A Priority: Normal
NCT ID: NCT00371592 Org: User:
Start: 09/30/06 End: 01/31/09 Due: 01/31/10

Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT00695877 Org: User:
Start: 02/08/09 End: 10/14/16 Due: 10/14/17

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00307177 Org: User:
Start: 08/31/04 End: 04/30/05 Due: 04/30/06

PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response

Phase: N/A Priority: Normal
NCT ID: NCT03098862 Org: User:
Start: 09/04/17 End: 12/23/20 Due: 12/23/21

Phase 1 Trial of Inactivated West Nile Virus Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT02337868 Org: User:
Start: 03/31/15 End: 12/16/16 Due: 12/16/17

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Phase: N/A Priority: Normal
NCT ID: NCT00042289 Org: User:
Start: 06/09/03 End: 09/30/20 Due: 09/30/21

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Phase: N/A Priority: Normal
NCT ID: NCT00001095 Org: User:
Start: - End: 10/31/99 Due: 10/31/00

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00001075 Org: User:
Start: - End: 07/31/07 Due: 07/31/08

Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT00094718 Org: User:
Start: 02/28/05 End: 04/30/05 Due: 04/30/06